Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma
Findings published in npj Precision Oncology and presented at ASCO 2026 by Aqtual and UHN’s Princess Margaret Cancer Centre demonstrate longitudinal blood-based monitoring of tumor microenvironment biology and resistance. CHICAGO — Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, today announced new findings demonstrating its […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.